AER-271 is a phosphonate precursor (prodrug) form of the selective aquaporin 4 (AQP4) inhibitor IMD-0354 (AER-270; hu/m/r IC50 = 420/390/210 nM using respective CHO AQP4 transfectants) with >5000-fold enhanced solubility. AER-271 is rapidly converted to AER-270 in vivo (plasma AER-270 Cmax = 500 ng/mL or 1.75 μM, 20 min post 10 mg AER-271/kg i.p.; C57BL/6 mice) and exhibits therapeutic efficacy in rodent models of brain damage by cardiac arrest or ischemic stroke (5-10 mg/kg ip. & 0.08 mg/h sc. in mice; 1-10 mg/kg iv. in rats).
Phosphonate precursor (prodrug) of the selective aquaporin 4 (AQP4) inhibitor IMD-0354 (AER-270) with in vivo efficacy in rodent models of brain damage.
The IKK-2 Inhibitor V, also referenced under CAS 978-62-1, controls the biological activity of IKK-2. This small molecule/inhibitor is primarily used for Inflammation/Immunology applications.
form
powder
form
solid
form
solid
assay
≥98% (HPLC)
assay
≥98% (HPLC)
assay
≥95% (HPLC)
Quality Level
100
Quality Level
100
Quality Level
100
storage temp.
−20°C
storage temp.
−20°C
storage temp.
2-8°C
solubility
DMSO: 2 mg/mL, clear
solubility
DMSO: >20 mg/mL
solubility
DMSO: 5 mg/mL, ethanol: 1 mg/mL
color
white to beige
color
-
color
white
Storage Class
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
